These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 1635498)

  • 21. Immunosuppressive preconditioning or induction regimens : evidence to date.
    Tan HP; Smaldone MC; Shapiro R
    Drugs; 2006; 66(12):1535-45. PubMed ID: 16956302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
    Marcus N; Khaghani A; Burke M; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
    [No Abstract]   [Full Text] [Related]  

  • 23. Collaborative Transplant Study--10-year report.
    Opelz G
    Transplant Proc; 1992 Dec; 24(6):2342-55. PubMed ID: 1465795
    [No Abstract]   [Full Text] [Related]  

  • 24. Tacrolimus (FK506) proves superior to OKT3 for treating episodes of persistent rejection following intrathoracic transplantation.
    Meiser BM; Uberfuhr P; Schulze C; Fuchs A; Mair H; Reichenspurner H; Kreuzer E; Reichart B
    Transplant Proc; 1997; 29(1-2):605-6. PubMed ID: 9123150
    [No Abstract]   [Full Text] [Related]  

  • 25. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 26. Acute cardiac ongoing rejection: comparison between different strategies.
    Forni A; Faggian G; Luciani GB; Lamascese N; Mazzucco A
    Transplant Proc; 2001 May; 33(3):2395-7. PubMed ID: 11377573
    [No Abstract]   [Full Text] [Related]  

  • 27. A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.
    Baldi A; Malaise J; Mourad M; Squifflet JP
    Transplant Proc; 2000 Mar; 32(2):429-31. PubMed ID: 10715467
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
    Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
    Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
    [No Abstract]   [Full Text] [Related]  

  • 29. Cytomegalovirus prophylaxis in pediatric renal transplant recipients.
    So S; Mayo C; McCullough C; Jendrisak M; Woodle S; Marsh W; Bailey T
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1414-5. PubMed ID: 8382865
    [No Abstract]   [Full Text] [Related]  

  • 30. Muromonab CD3: a reappraisal of its pharmacology and use as prophylaxis of solid organ transplant rejection.
    Wilde MI; Goa KL
    Drugs; 1996 May; 51(5):865-94. PubMed ID: 8861551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of immunosuppressive agents for solid organ transplantation in children.
    Coelho T; Tredger M; Dhawan A
    Pediatr Transplant; 2012 Mar; 16(2):106-22. PubMed ID: 22360399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody therapy as an induction regimen in pediatric renal transplantation.
    Ettenger RB
    Transplant Proc; 1999 Sep; 31(6):2677-8. PubMed ID: 10500765
    [No Abstract]   [Full Text] [Related]  

  • 33. Antithymocyte globulin as the primary treatment for renal allograft rejection.
    Nelson PW; Cosimi AB; Delmonico FL; Rubin RH; Tolkoff-Rubin NE; Fang L; Russell PS
    Transplantation; 1983 Nov; 36(5):587-9. PubMed ID: 6356523
    [No Abstract]   [Full Text] [Related]  

  • 34. ATG versus OKT3 in the treatment of steroid-resistant rejection following living-related donor renal transplantation.
    Uslu A; Tokat Y; Ok E; Unsal A; Ilkgul O; Kaplan H
    Transplant Proc; 1997 Nov; 29(7):2805-6. PubMed ID: 9365571
    [No Abstract]   [Full Text] [Related]  

  • 35. Correlation between Banff classification and reversal of acute renal rejection.
    Kokado Y; Kyo M; Takahara S; Ichimaru N; Wang JD; Toki K; Miki T; Okuyama A
    Transplant Proc; 1998 Nov; 30(7):3064-6. PubMed ID: 9838350
    [No Abstract]   [Full Text] [Related]  

  • 36. Muromonab-CD3 and antithymocyte globulin in renal transplantation.
    Burk ML; Matuszewski KA
    Ann Pharmacother; 1997 Nov; 31(11):1370-7. PubMed ID: 9391693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Monoclonal antibodies in organ transplantation].
    Vanhove B
    Med Sci (Paris); 2009 Dec; 25(12):1121-5. PubMed ID: 20035690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relative clinical impact of cyclosporine vs steroid induction therapy on renal function and allograft rejection in heart transplant recipients.
    Hanrahan JS; Ibrahim H; Tolman D; Kirchberg D; Salter D; Guerraty A; Mohanty PK
    Transplant Proc; 1996 Aug; 28(4):2107-8. PubMed ID: 8769168
    [No Abstract]   [Full Text] [Related]  

  • 39. Triple drug maintenance therapy in renal transplantation.
    Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
    Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
    [No Abstract]   [Full Text] [Related]  

  • 40. Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression.
    Bush WW
    AACN Clin Issues; 1999 May; 10(2):253-69; quiz 304-6. PubMed ID: 10578712
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.